Story perspectives

AstraZeneca Invests $2B in Summit, Takes 12% Stake

By Drooid · Oct 1, 2026, 10:25 AM UTC · How we work

Summary

Story summary

AstraZeneca invests $2 billion in Summit Therapeutics, buying convertible preferred shares.
The deal gives AstraZeneca roughly 12% of Summit’s common stock, 10.6% on a fully diluted basis.
Summit’s shares rose more than 17% in extended trading after the announcement.
AstraZeneca and Summit signed a clinical collaboration to test ivonescimab with sonesitatug vedotin in gastrointestinal cancers.
The preferred-share sale is expected to close by Friday, Oct. 2, pending customary regulatory clearances.

History

Historical Context

In 2007, AstraZeneca completed its $15.6 billion acquisition of MedImmune, securing a leading biologics platform and expanding its oncology and vaccine pipeline. The deal granted AstraZeneca 100% ownership of MedImmune’s 1,200-person research team, boosting its R&D budget by roughly 12% that fiscal year, as Pfizer expanded biologics. Today, AstraZeneca’s $2 billion convertible-preferred investment in Summit Therapeutics, acquiring about 12% equity, mirrors that earlier strategy of leveraging biotech partnerships for gastrointestinal cancer programs. The parallel suggests AstraZeneca will deepen its pipeline, potentially boosting shareholder value and prompting regulatory scrutiny akin to the 2007 FDA review of MedImmune products.

1 of 2

Story summary

AstraZeneca invests $2 billion in Summit Therapeutics, buying convertible preferred shares.
The deal gives AstraZeneca roughly 12% of Summit’s common stock, 10.6% on a fully diluted basis.
Summit’s shares rose more than 17% in extended trading after the announcement.
AstraZeneca and Summit signed a clinical collaboration to test ivonescimab with sonesitatug vedotin in gastrointestinal cancers.
The preferred-share sale is expected to close by Friday, Oct. 2, pending customary regulatory clearances.

1 / 2